California researchers are now suggesting that analyzing copies of genes may point to new treatments for ovarian cancer as well as for other tumor types. The researchers contend that targetable genetic changes in tumors should not be limited to mutations.
Oncologists today now have a much greater understanding of the mutational landscape underlying some tumors. However, in many respects it is still a daunting task—one that may require more effective interpretation tools.
A new German multicenter study is suggesting that lutetium-177 (Lu-177)-labeled PSMA-617 may be a promising new therapeutic agent for radioligand therapy in men with metastatic castration-resistant prostate cancer.
A study recently published is suggesting that a key drug target, CDK4/6, regulates a cancer metastasis protein, and may play a role in combating metastasis in triple-negative breast cancer. In addition, this new finding may point to a new way of preventing metastasis in other cancers.